Tonix Pharm Hld (TNXP) |
|
0.9288 0.017 (1.85%)
|
01-21 00:54 |
|
Open: |
0.931 |
Pre. Close: |
0.9119 |
|
High:
|
0.955 |
Low:
|
0.882 |
|
Volume:
|
24,308,278 |
Market Cap:
|
246M |
|
|
|
|
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300, a second live replicating vaccine candidate for the prevention of COVID-19 that employs bovin parainfluenza virus as the vector. In addition, the company's lead CNS candidate is TNX-102 SL, which is in Phase 3 development for the management of fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR (tianeptine oxalate controlled-release tablets) that is in Phase 1 development for depression; and TNX-1900, an intranasal oxytocin as a non-addictive treatment for migraine and cranio-facial pain. Additionally, its preclinical pipeline includes TNX-1600, a triple reuptake inhibitor for posttraumatic stress disorder; TNX-1500, a monoclonal antibody to prevent and treat organ transplant rejection and autoimmune conditions; and TNX 1700, a recombinant modified form of Trefoil Family Factor 2 to treat gastric and pancreatic cancers. The company was founded in 2007 and is based in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.951 - 0.955 |
0.955 - 0.959 |
|
Low:
|
0.871 - 0.874 |
0.874 - 0.879 |
|
Close:
|
0.923 - 0.929 |
0.929 - 0.936 |
|
Technical analysis |
as of: 2021-01-20 4:53:00 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.34 One year: 1.57 |
| Support: |
Support1: 0.77 Support2: 0.54 |
| Resistance: |
Resistance1: 1.15 Resistance2: 1.34 |
| Pivot: |
0.83  |
| Moving Average: |
MA(5): 0.94 MA(20): 0.78
MA(100): 0.72 MA(250): 0.79 |
| MACD: |
MACD(12,26): 0.08 Signal(9): 0.07 |
| Stochastic oscillator: |
%K(14,3): 54.17 %D(3): 58.54 |
| RSI: |
RSI(14): 65.76 |
| 52-week: |
High: 2.46 Low: 0.39 Change(%): -33.2 |
| Average Vol(K): |
3-Month: 2090511 10-Days: 5654538 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.TNXP has closed below upper band by 26.2%. Bollinger Bands are 97.6% wider than normal. The large width of the bands suggest high volatility as compared to TNXP's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 19 Jan 2021
You Need to See this stock? Tonix Pharmaceuticals Holding Corp. (TNXP) - Armenian Reporter
Sun, 17 Jan 2021
Hot Stock on Spotlight: Tonix Pharmaceuticals Holding Corp. (TNXP) - Armenian Reporter
Thu, 07 Jan 2021
Further Research into Psilocybin Opens New Doors for Treatment - PR Newswire UK
Tue, 05 Jan 2021
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection - Yahoo Finance
Thu, 24 Dec 2020
BUZZ-U.S. STOCKS ON THE MOVE-Alibaba, Altimmune, Tonix - Nasdaq
Wed, 11 Nov 2020
Tonix Pharmaceuticals to Participate in Upcoming November Conferences - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
192 |
| Shares Float (M) |
156 |
|
% Held by Insiders
|
0.05 |
|
% Held by Institutions
|
5.25 |
|
Shares Short (K)
|
573 |
|
Shares Short P. Month (K)
|
791 |
Stock Financials |
|
EPS
|
-0.850 |
|
EPS Est This Year
|
-3.020 |
|
EPS Est Next Year
|
-2.470 |
|
Book Value (p.s.)
|
0.450 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-66.1 |
|
Return on Equity (ttm)
|
-116.4 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.220 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-41 |
|
Levered Free Cash Flow (M)
|
-31 |
Stock Valuations |
|
PE Ratio
|
-1.09 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.06 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-4.31 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
